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The NetherlandsA B S T R A C TObjectives: Some argue that generic preference-based measures
(PBMs) are not sensitive to certain disease-specific improvements. To
overcome this problem, new condition-specific PBMs (CS-PBMs) are be-
ing developed, but it is not yet clear how such measures compare with
existing generic PBMs. Method: We generated CS-PBMs from three
ondition-specific questionnaires (Health Assessment Questionnaire
or arthritis, Quality of Life Questionnaire for Cancer 30 for cancer, and
ultiple Sclerosis Impact Scale 29 for multiple sclerosis). First, the
uestionnaires were reduced in content, and then, a time trade-off
tudy was conducted in the general public (N  402) to obtain weights
associated with the dimensions and levels of the new questionnaire.
Finally, we compared utilities obtained by using the CS-PBMswith util-
ities obtained by using the EuroQol five-dimensional (EQ-5D) question-
naire in four data sets. Results: Utility values generated by the CS-
PBMs were higher than those of the EQ-5D questionnaire. The Health
Instit
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doi:10.1016/j.jval.2011.12.003Assessment Questionnaire–based measure for arthritis proved to be
insensitive to comorbidities. Measures based on the Multiple Sclerosis
Impact Scale 29 and the Quality of Life Questionnaire for Cancer 30
discriminated comorbidities and side effect equally well as the EQ-5D
questionnaire and were more sensitive than the EQ-5D questionnaire
for mild impairments. Conclusions: The introduction of PBMs that are
specific to a certain disease may have the merit of sensitivity to dis-
ease-specific effects of interventions. That gain, however, is traded off
to the loss of comparability of utility values and, in some cases, insen-
sitivity to side effects and comorbidity. The use of a CS-PBM for cost-
utility analysis is warranted only under strict conditions.
Keywords: patient-reported outcome measures, preference-based
measures, time trade-off, utility.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
A preferred method for generating the quality adjustment re-
quired for the computation of quality-adjusted life-years is
through generic preference-based measures (PBMs) such as the
EuroQol five-dimensional (EQ-5D) questionnaire [1] or the health
utilities index [2]. Some argue that such generic PBMs are not sen-
itive to certain disease-specific improvements. Consequently,
he existing PBMs may not always be the best tool to assess the
ffect of an intervention. To overcome this problem, new condi-
ion-specific PBMs (CS-PBMs) have been developed, for example,
or asthma [3] and urinary incontinence [4]. Not much is known,
owever, about how these new instruments comparewith generic
nstruments such as the EQ-5D questionnaire. It is feared that
sing CS-PBMs may lead to the exaggeration of health problems
ue to a focusing effect, render comparison of utility values im-
ossible, because utilities are derived from different PBMs, and
ay be insensitive to comorbidities [5,6]. Evidence, however, is
carce. In this study, three CS-PBMs were developed for the pur-
ose of exploring these and other issues, one for arthritis (based on
he Health Assessment Questionnaire [HAQ]), one for multiple
clerosis (MS) (based on the Multiple Sclerosis Impact Scale 29
* Address correspondence to: Matthijs M. Versteegh, iMTA/iBMG,
nology Assessment, Erasmus University of Rotterdam, PO Box 173
E-mail: versteegh@bmg.eur.nl.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.[MSIS-29]), and one for cancer (based on the European Organiza-
tion for Research and Treatment of Cancer Quality of Life Ques-
tionnaire for Cancer 30 [QOL-C30]).
A PBM is a questionnaire with a scoring function to weight the
responses according to preferences for certain health conditions
over others. These preferenceweights are elicited in studieswhere
respondents are asked to express their preference for a health
state, for instance, using time trade-off (TTO) or standard gamble.
Existing generic PBMs such as the EQ-5D questionnaire and the
health utilities index were developed to have a standardized tool
to measure the health-related quality of life for the quality adjust-
ment part of the quality-adjusted life-year. These generic prefer-
ence-based instruments aim to measure the quality of life on a
sufficient degree of generality to allow comparisons across condi-
tions. For these instruments, the key trade-off is between gener-
ality of the included health dimensions to allow cross-disease
comparisons and sensitivity to pick up (relevant) treatment effects
[5]. The EQ-5D questionnaire, for example, consists of five items
with three levels measuring mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. The choice to include
only these basic dimensions of health ensures the level of gener-
ality that is required for comparison across diseases at the poten-
tial cost of losing sensitivity for disease-specific complaints. For
ute of Health Policy and Management/Institute for Medical Tech-
00 DR Rotterdam, The Netherlands.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
505V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 0 4 – 5 1 3example, the view is widely held that the EQ-5D questionnaire is
not an appropriatemeasure to assess the quality of life of patients
with sensory problems (bad eyesight or hearing problems), be-
cause sensory problems are beyond the scope of health defined by
dimensions of the EQ-5D questionnaire [7]. Another perceived
problem of the EQ-5D questionnaire is that very mild conditions
cannot be adequately assessed by using only three levels of im-
pairment because of low ceiling sensitivity [8,9].
The increased use of economic evaluations by health author-
ities seems to have created a sense of urgency within the health
assessment community to deal with the shortcomings of ge-
neric PBMs. In recent years, new CS-PBMs have emerged for
which the development was motivated by either the absence of
generic PBMs in a specific context or the judgment that generic
PBMs would not be appropriate for a condition. Contrary to ge-
neric instruments, a CS-PBM contains dimensions specifically
targeted at the affected population. In terms of the trade-off
mentioned above, these instruments are expected to demon-
strate superior sensitivity to specific diseases, although this
may come at the cost of comparability of utility values across
conditions. Because of the difference in the scope of different
instruments, utility values derived from a CS-PBM may not be
comparable with those derived from a generic instrument, even
though they seem to lie on the same 0-to-1 scale. Although the
development of CS-PBMs is valuable for research purpose, for
example, to better investigate the shortcomings of generic
PBMs, there is concern about the application of CS-PBMs in eco-
nomic evaluations. Unfortunately, empirically founded guid-
ance on how and when to apply CS-PBMs is absent.
There has been little reflection so far on the comparability of
the obtained quality-of-life weights to those obtained from ge-
neric PBMs. Specific issues in comparability are described in a
recent expert editorial [5]. First, CS-PBMs may cause an exag-
geration of health problems (reflected by low utility values) due
to focusing effects. When the health states in a preference elic-
itation study consist of a set of disease-related items, rather
than general items of health-related quality of life, the context
of the valuation is narrower, possibly leading to lower utility
values. The logic behind this hypothesis is that narrow-focused
items may seem less important when presented in a wider con-
text of general health (e.g., having a cold may seem less severe
when presented alongside problems with mobility), but may
seem quite problematic when presented separately. This may
result in a downward bias on preference values when compared
with generic PBMs. Second, a CS-PBM might have difficulty cap-
turing comorbidities as the focus is on disease-related items.
This may result in an upward bias on utility values. Further-
more, developing a CS-PBM is not a clear-cut exercise. Re-
searchers facemany decisions, such as the reduction of items in
a questionnaire, the selection of health states (how many and
which?) that have to be valued to develop a PBM [7], on the
valuation method (e.g., TTO or standard gamble?), and on the
modeling approach. How these decisions are dealt with may
differ per study, which decreases comparability.
The primary aim of this article was to provide empirical evi-
dence about the comparability of CS-PBMs and generic PBMs. To
do so, three CS-PBMs were developed from existing question-
naires. The values generated by these CS-PBMs were then com-
pared with EQ-5D questionnaire values for the same patient sam-
ples. By providing empirical evidence we hope to provide a better
understanding of the effects of using CS-PBMs and contribute to
the development of guidance for their use. This is important, be-
cause it can be expected that in the nearby futuremore cost-utility
analyses will contain utilities based on condition-specific mea-
sures.Methods
Questionnaires for CS-PBM development
The CS-PBMs were developed from the HAQ [10], the MSIS-29 [11],
and the QLQ-C30 [12]. These instruments were selected on the
basis of expert advice and commonality of use within clinical set-
tings. The HAQ is a widely used questionnaire in rheumatology to
measure functional abilities by using 20 items with four levels
spread across eight domains (dressing, rising, eating, walking, hy-
giene, reach, grip, and usual activities). The scale has been shown
to be unidimensional [13]. TheMSIS-29measures the impact ofMS
on a physical and psychological dimension. Dimensionality of the
subscales has been confirmed by using Rasch analysis [14]. The
QLQ-C30 (version 2) is a cancer-specific questionnaire consisting
of 30 items. These items cover five functional scales, nine symp-
tom scales, and a global health status scale. These questionnaires
were chosen because they differ in scope and because EQ-5Dques-
tionnaire datawere available for the purpose of comparing results.
For MSIS-29, it has been shown that the physical scale is better
capable of discriminating among subcategories of the clinically
assessed Expanded Disability Status Scale (EDSS) than is the
EQ-5D questionnaire [15]. Therewas no evidence known to us on a
lack of responsiveness of the EQ-5D questionnaire or the superi-
ority of the condition-specific measures HAQ and QLQ-C30 in ar-
thritis and cancer, respectively.
Reducing the content of the questionnaires
Developing a PBM from an existing questionnaire does not lead to
an entirely new instrument but attaches weights to some of the
items of the existing questionnaire. Such an approach generally
requires a method to reduce the questionnaire content because
only a limited number of items can be valued in a preference elic-
itation study [7]. Typically, only a fraction of the total amount of all
theoretically possible health states is valued. The values for the
remainder of the health states are estimated through modeling
techniques.
The optimal number of items in a health state was considered
to be in the order of five to nine items, because more items may
cause difficulties for respondents in the valuation study [7]. The
HAQ, MSIS-29, and QLQ-C30, respectively, contain 20, 29, and 30
items, and so reduction of content was required. Relevant and
well-functioning items from the questionnaires were selected by
using the following criteria proposed by others [16]: 1) the itemhad
to fit the Raschmodel, 2) the item had to meet basic psychometric
criteria, and 3) the selected items had to be approved by a clinical
expert. Four data sets were available for these analyses: the Rot-
terdam Early Arthritis CoHort for the HAQ (N  738), the Multiple
Sclerosis Risk Sharing SchemeMonitoring Study (N 1295) for the
MSIS-29, and the Haemato Oncology Foundation for Adults in the
Netherlands 24 (pooled N  716) and Haemato Oncology Founda-
tion for Adults in the Netherlands 25 (pooled N 789) trials for the
QLQ-C30. The data set characteristics are described in detail in
Versteegh et al. [15]. A set of a priori criteria was used to determine
which items were suitable for the health state description [16,17].
Because it was expected that neither of these criteria could be
sufficient on its own, the three criteria were employed “side by
side” (i.e., no hierarchical order).
Criterion 1: Fit to the Rasch model
Rasch analysis was used to test the psychometric validity of a
scale and to identify well-functioning items. The Rasch model as-
sumes that the probability of scoring level  on item i is a logistic
function of the relative distance between the item location (how
much disability it represents) and the respondent location (how
disabled the patient is) [18].
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whether the item 1) has ordered thresholds (having more of the
latent trait  results in endorsing a higher level answer category
[19]), 2) fits the Rasch model (fit residual 2.5 and nonsignificant
bonferroni-adjusted probability), 3) combined scale fits the Rasch
model (described by a nonsignificant item-trait interaction chi-
square probability [19]), and 4) shows no differential item func-
tioning. After each single scale amendment the analysiswas rerun
for the remaining items. Rasch analysis was performed on the
dimensional structure originally suggested by the questionnaires.
Criterion 2: Psychometric properties
Psychometric criteria were laid alongside the Rasch results to
come to a final selection of items amenable for valuation. The
functioning of the items was tested by investigating the loading of
items on factors identified by factor analysis; missing data; inter-
nal consistency of items with its scale score; distribution of the
responses on an item including floor and ceiling effects; and re-
gression coefficients between a general health indicator and an
item. Psychometric analyses were applied to the full data sets.
Criterion 3: Expert opinion
The selected items from the questionnaires were presented to ex-
perts in the respective fields. Experts from the Erasmus Medical
Centre and the VU Amsterdam Medical Centre were consulted to
gain insight into important aspects of the disease and to evaluate
the result of the previous selection process.
Health state selection
Even after data reduction the selected set can still generate an
enormous amount of possible health states; therefore, a fractional
factorial design was favored over a full factorial design. The QLQ
designwas a level-balanced design,meaning that all levels of each
item occurred with the same frequency. Within the balanced de-
sign, health states covered the entire spectrum of severity, mea-
sured by averaging the item levels of a health state. For the
MSIS-29 and the HAQ, items and levels were selected with an or-
thogonal main effects plan (OMEP) as is applied in other studies
[20,21] to ensure zero statistical correlation between the attri-
butes. The set was complemented with a selection of the most
observed health states (four or more observations) over the sever-
ity range of the questionnaire. TTO values estimatedwith additive
main-effect models (one based on the OMEP states and one based
on the OMEP and the most observed states) were compared with
the observed TTO values of the most occurring states by using
standard predictive performance measures such as mean abso-
lute error (MAE) to see whether the addition of these states led to
improved prediction of the most frequently occurring states.
Table 1 – Items selected for the TTO valuation exercise.
HAQ MSIS
● HAQ1 Stand up from a straight chair
● HAQ2 Walk outdoors on flat ground
● HAQ3 Get on / off toilet
● HAQ4 Reach and get down a 5-pound
object (such as a bag of sugar) from
just above your head
● HAQ5 Open car doors
● MSIS1 Problems wi
● MSIS2 Being clums
● MSIS3 Limitations
leisure activities at
● MSIS4 Difficulties u
everyday tasks
● MSIS5 Having to cu
of time you spent o
daily activities
● MSIS6 Feeling men
● MSIS7 Feeling irrita
short tempered● MSIS8 Problems concenThe final designwas blocked. In such a design respondents value
a number of health states that belong to the same “block.” Themean
severity of the combination of items in a blockwas similar andmea-
sured through summing the level scores of the items in a block.
Health state valuation with time trade-off method
The preferences of a sample of the general public were elicited
through a TTO exercise for each of the selected health states of the
questionnaires. To optimize comparability to generic PBMs, the
CS-PBM health states were valued with the same TTO protocol,
the same computer-assisted personal interview tool, the same
procedure to measure states “worse than dead,” and the same
rescore procedure of negative values (negative TTO scores were
rescaled to have a range between 1 and 0 with (t/xt) as was
adopted in the Dutch EQ-5D questionnaire valuation study) [22].
nlike the Dutch EQ-5D questionnaire valuation study, this study
as performed in group sessions, which has previously been
hown to produce comparable TTO results [23].
The TTO exercisewas self-administered through a digital tool for
TO elicitation (computer-assisted personal interviews) in groups
ith about 12 to 25 respondents per session. Each sessionwas super-
ised by three to four researchers to offer assistance if needed. Prior
o the task, respondents received 30 minutes of instructions by re-
earchers M.V. or A.L. including examples of the TTO computer pro-
ram projected on a large screen. The task was piloted by M.V. and
.L. in a sample of 18 respondents to ensure the introduction, the
omputer program, and the organization of the task were feasible.
The three questionnaireswere presented separately in the TTO
xercise and in all possible orders (e.g., first HAQ, then MSIS, then
LQ).Within the TTO exercises, health states were presented ran-
om to individuals.
Respondents
Respondents were selected by a marketing agency that requited a
sample resembling the Dutch general population in age, gender,
and education. Respondents were approached by phone and
asked whether they were interested in contributing to a task to
value descriptions of health states. Respondents received a finan-
cial reward of €35 upon completion of the three TTO exercises.
Respondents were removed from the analyses when the results
indicated they valued themajority of logically worse states higher
than logically better states in a set (i.e., HAQ state 11112 is logically
better than HAQ state 14444).
Modeling of the TTO values
Once the TTO study had been performed, the preference values
observed for the selected health states were used to estimate
QLQ-C30
ur balance
r social and
e
your hands in
n the amount
rk or other
fatigued
mpatient or
● QLQ1 Trouble taking a long walk
● QLQ2 Limited in doing either your work or
other daily activities
● QLQ3 Have you had pain
● QLQ4 Have you felt nauseated
● QLQ5 Were you tired
● QLQ6 Difficulty in concentrating on things
● QLQ7 Did you worry
● QLQ8 Has your physical condition or
medical treatment interfered with your
social activities-29
th yo
y
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t dow
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ble, itrating
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ing. Because individuals value more than one health state there
are multiple observations for each individual. Random effects
models were estimated to assess how the predictors (the items
and their levels) influence the dependent variable (the mean
observed TTO value). In these random effects models, the item
levels were treated as dummy variables with dummy coding.
The constant term was treated as an additional decrement for
having any item level other than the base case (“no problems”),
which is similar to the EQ-5D questionnaire model. The values
predicted by this random effects model will be referred to as the
PBM results (e.g., HAQ-PBM). Models were required to have sig-
nificant predictors and worse scores on the levels ought to be
represented by larger utility decrements. Model performance
was assessed by comparing the MAE of observed and predicted
values. Models were estimated until meeting those criteria.
Only the most parsimonious models are presented. To keep op-
timal comparability between the developed CS-PBMs, models
were estimated from the items only, without interaction effects
or a “worst-value” dummy variable, which is 1 for every item on
the lowest level. Interaction effects were not estimated because
the study design was a main effects design.
Hypotheses and analyses
To investigate the properties of PBMs developed from existing
questionnaires, several hypotheses were tested. First, it was
tested whether the TTO values could be successfully modeled.
For HAQ and MSIS, the TTO random effects models were fitted
on both the full data set (including “most observed” health
states) and on the subset consisting of health states originating
from the OMEP. This was done to test whether an OMEP alone is
sufficient to estimate the utility values of the most occurring
health states. Second, it was investigated whether CS-PBMs
yielded lower mean utility values than did a generic measure,
which was hypothesized to reflect that a downward bias on
utility values resulting from a focusing effect might outweigh
the upward bias on utility values resulting from a narrower
scope of the CS-PBM. Third, it was tested with Wilcoxon rank-
sum tests, to account for the non-normal distribution of utility
values, whether the developed CS-PBMs had a more narrow fo-
cus and were therefore less sensitive to comorbidities (in arthri-
tis and MS data sets) or side effects (non-Hodgkin’s lymphoma
data set) than the EQ-5D questionnaire. Side effects had World
Health Organization performance status 2 or higher, represent-
ing the inability to carry out work activities due to the condition.
Fourth, we assessed discriminative properties of the new mea-
sures by using clinical indicators. For arthritis, the Disease Ac-
tivity Score-28 was used, which is based on a count of tender
joints and the erythrocyte sedimentation rate. It distinguished
between high, moderate, and low disease activity and remis-
Table 2 – TTO study design following item selection.
Number of items
Total number of health states to be valued
States identified by OMEP (used in study after fold-over)
Number of most occurring states included
Number of states valued by one individual (total  33)
Number of blocks*
Expected number of observations per health state (N  400/number o
HAQ, Health Assessment Questionnaire; MSIS, Multiple Sclerosis Im
plan; QLQ, Quality of Life Questionnaire; TTO; time trade-off.
* One block consist of a number of states, and all the states in one bsion. For MS, the EDSS was used, which, when rounded to inte-gers, distinguishes 11 categories of increasing disability. For
cancer, we used the World Health Organization performance
status score (or Eastern Cooperative Oncology Group), which
distinguishes six categories, from 0 to 6 (death). Lastly, respon-
siveness was measured in the cancer population by using effect
size (Cohen’s d) and mean change in the cancer population, for
hich follow-up measurements were available in the data set.
All results were compared with utilities of the Dutch EQ-5D
uestionnaire tariff [22].
Software
For Rasch analysis, the RUMM 2020 software (Rumm Laboratory
Pty Ltd., Perth, Western Australia) was used. Psychometric analy-
sis was performed in SPSS 17.0 (SPSS Inc., Chicago, IL, USA), and all
hypothesis testing andmodeling effortswere performed in STATA
11.0 (StataCorp. 2009, College Station, TX, USA).
HAQ MSIS QLQ
5 8 8
56 100 105
15 (30) 32 (64) N/A
26 36 N/A
8 10 15
7 10 7
cks) 57 40 57
Scale; N/A, not applicable/available; OMEP, orthogonal main effects
re valued by one individual.
Table 3 – Respondent characteristics.
TTO
study
sample
Dutch
population
norms*
N 402 –
Gender, M/F (%) 46/54 49.5/50.5
Age (y)
Mean (SD) 45 (15.5) 40.1
Min–max 15–76 –
Age group (y) (%)
20 4.8 23.7
20–40 37.6 25.3
40–65 46.9 35.7
65–80 10.4 11.4
80 0.3 3.9
Education (%)
High 34 27
Medium 35 31
Low 25 33
Missing/else 6 9
Mean (SD) time to complete TTO (min)
HAQ 8 states 8 (4.6) –
MSIS 10 states 10 (5.8) –
QLQ 15 states 12.7 (5.8) –
HAQ, Health Assessment Questionnaire; MSIS, Multiple Sclerosis
Impact Scale; N/A, not applicable/available; OMEP, orthogonalmain
effects plan; QLQ, Quality of Life Questionnaire; TTO; time trade-off.f blo
pact* Statistics Netherlands, 2009 figures.
rosi
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Item and level selection
The selected items per questionnaire are presented in Table 1, and
all met the criteria of the Rasch analysis, psychometric analysis,
and expert opinion. The full results of the selection of items and
levels are described inAppendixA. A table of the results of the Rasch
analysis is presented in Appendix B (see Appendices in online Sup-
plemental Materials found at doi: 10.1016/j.jval.2011.12.003).
Resulting study design
Given the many items and levels in the study, we chose a frac-
tional factorial blocked design. Health states were presented in
blocks, so that one individual values one block containing several
health states. The design is listed in Table 2.
Fig. 1 – (A) Mean utility values of health states. (B) Percentag
HAQ, Health Assessment Questionnaire; MSIS, Multiple Scle
Table 4 – Final random effects model characteristics.
HAQ-PBM*
Random effects mean models
R-square* 0.94
MAE 0.028
MAE most observed states 0.022
Illogical sign or order of variables 0
Insignificant predictors 0
Possible range 0.32–1
HAQ-PBM, Health Assessment Questionnaire-preference-based me
Scale-preference-based measure; QLQ-PBM, Quality of Life Questionn
* Model based on states from the orthogonal design and the most ob
† Model based on states from the orthogonal design.Data quality
Four hundred two respondents participated in the computer-as-
sisted TTO study and resembled the Dutch population (Table 3).
Respondents were excluded from the analyses if they had valued
the majority of logically better states lower than logically worse
states in one block (8 exclusions for HAQ, 17 for MSIS, and 7 for
QLQ). Average time to value one health state in the TTO exercise
was about 1 minute. Total time per block was highest for QLQ (15
health states, about 12 minutes), followed by MSIS (10 health
states, 10minutes) and HAQ (8 health states, 8minutes). Although
two separate researchers took turns in holding the introductory
talks, this did not bias the TTO responses (Wilcoxon rank-sum
test: P 0.05). On average, womenhad higher utility values (t –test:
P  0.00) for all three questionnaires.
The mean utility of the health states and the percentage of
responses indicating a state to be worse than dead are presented
in Figure 1A, B.
respondents who classified a state as worse than dead.
s Impact Scale; QLQ, Quality of Life Questionnaire.
MSIS-PBM† MSIS-PBM* QLQ-PBM
0.68 0.78 0.88
0.034 0.04 0.033
0.057 0.043 –
0 0 0
0 0 0
0.40–1 0.42–1 0.34–1
; MAE, mean absolute error; MSIS-PBM, Multiple Sclerosis Impact
preference-based measure.
d states.e ofasure
aire-
serve
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TTO values were modeled for each of the three questionnaires
with random effects mean prediction models. For the HAQ, using
only the OMEP-based health states had toomuch variation in TTO
scores between respondents to estimate a model with significant
predictors and logical negative signs for each of the dummy vari-
ables (increasing negative decrements per item level of severity).
Estimating the model on all the available data (thus including the
“most observed” states) yielded a well-functioning mean predic-
tion model. The prefinal MSIS-29 model had insignificant predic-
tors for three variables MSIS3; the prefinal QLQ-C30 model had
insignificant predictors for two variables. In all instances, merging
the levels with the adjacent categories resolved the problem.
Model characteristics are summarized in Table 4, and full models
are presented in Table 5.
When theMSIS-29 predictionmodelwas based on all the states
(thus including the most observed states), the prediction error for
the most observed states was reduced (MAE  0.043 compared
with MAE  0.057). When the MSIS-29 TTO values were modeled
without the “most observed” states, the utility values were gener-
ally higher, which caused the utility values of some of the “most
observed” states to be overestimated (Fig. 2).
Comparability of mean utility values
In the four data sets, the developed CS-PBMs based on the models
presented in Table 5 produced a higher mean utility score for pa-
tients than did the EQ-5D questionnaire (Table 6). Especially, the
HAQ-PBM (mean  0.91) had a much higher mean utility value
than did the EQ-5D questionnaire (mean 0.68). Furthermore, the
difference between themean EQ-5D questionnaire score in arthri-
tis and the mean EQ-5D questionnaire score in MS was 0.06 while
Table 5 – Coefficients of random effects models with TTO v
HAQ-PBM MSI
Coefficient SE C
haq1_2 0.005 0.001 ms1_2
haq1_3 0.031 0.002 ms1_3
haq1_4 0.121 0.002 ms1_4
haq2_2 0.029 0.001 ms2_2
haq2_3 0.091 0.002 ms2_3
haq2_4 0.144 0.002 ms2_4
haq3_2 0.042 0.001 ms3_3
haq3_3 0.055 0.002 ms3_4
haq3_4 0.213 0.002 ms4_2
haq4_2 0.022 0.001 ms4_3
haq4_3 0.041 0.002 ms4_4
haq4_4 0.074 0.002 ms5_2
haq5_2 0.016 0.001 ms5_3_4†
haq5_3 0.038 0.002 ms6_2
haq5_4 0.044 0.002 ms6_3
Constant 0.918 0.002 ms6_4
ms7_3
ms7_4
ms8_2
ms8_3
ms8_4
Constant
HAQ-PBM, Health Assessment Questionnaire-preference-based mea
sure; QLQ-PMB, Quality of Life Questionnaire-preference-based meas
* MSIS model with most observed health states included.
† Both ms5_3 and ms5_4 have the same decrement.
Bold indicates all coefficients were significant at P0.05.the difference between the mean HAQ-PBM and the MSIS-PBMscore was 0.24. The QLQ-C30-PBM–based utility values had the
highest correlation with EQ-5D questionnaire utility values. Both
the MSIS-PBM and the QLQ-PBM, however, have increased sensi-
tivity compared with the EQ-5D questionnaire. Where the EQ-5D
questionnaire scores full health (a utility value of 1), theMSIS-PBM
and the QLQ-PBM report decrements in utility for 99 and 185 pa-
tients, respectively (Table 7).
Comorbidities and side effects
The HAQ-PBM could not discriminate between patients with and
without comorbidity (other vascular disorders and psychiatric disor-
ders) when the EQ-5D questionnaire could (Table 8). For arthritis pa-
as dependent variable.
B* QLQ-PMB
ient SE Coefficient SE
16 0.003 qlq1_2 0.027 0.001
43 0.003 qlq2_2 0.020 0.002
89 0.003 qlq2_3 0.047 0.002
18 0.003 qlq2_4 0.068 0.002
47 0.003 qlq3_3 0.079 0.002
47 0.003 qlq3_4 0.213 0.001
55 0.002 qlq4_2 0.018 0.002
71 0.002 qlq4_3 0.055 0.002
61 0.002 qlq4_4 0.089 0.002
01 0.003 qlq5_2 0.021 0.002
08 0.003 qlq5_3 0.031 0.002
32 0.003 qlq5_4 0.037 0.002
57 0.002 qlq6_2 0.004 0.002
20 0.003 qlq6_3 0.039 0.002
35 0.003 qlq6_4 0.052 0.002
59 0.003 qlq7_3 0.009 0.002
24 0.002 qlq7_4 0.047 0.002
38 0.002 qlq8_2 0.008 0.002
37 0.003 qlq8_3 0.041 0.002
59 0.003 qlq8_4 0.060 0.002
73 0.003 Constant 0.944 0.002
59 0.005
MSIS-PBM, Multiple Sclerosis Impact Scale-preference-based mea-
TTO, time trade-off.
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510 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 0 4 – 5 1 3tients with diabetes, hypercholesterolemia, or thyroid disease, the
HAQ-PBM showed higher utility values for individuals with the dis-
orderwhile the EQ-5D questionnaire signaled the expected direction
of differences. The MSIS-PBM also showed higher utilities for pa-
tients with asthma and high blood pressure (rather than without),
but this was concordant with the differences indicated by the EQ-5D
questionnaire. Both the MSIS-PBM and the EQ-5D questionnaire
pickedupsignificantdifferencesbetweenMSpatientswithandwith-
out depression (P  0.05). In the non-Hodgkin’s lymphoma data set,
atients with side effects and infections as a result of treatment had
ower (P0.05)utility values inboth theEQ-5Dquestionnaireand the
LQ-C30 than did patient without side effects and infections, except
or hair loss. All significant differences were at least half a SD except
or comorbidity “depression” in the MS data set and “other side ef-
ects” in the non-Hodgkin’s lymphoma data set.
Discriminative ability and responsiveness
Utilities of all instruments decreased with an increase in severity
as assessed by the clinical indicator (Table 9). The utilities of the
HAQ-PBM, however, failed to distinguish between low and mod-
erate disease activities. The EQ-5D questionnaire did so accu-
rately. As has previously been shown, the EQ-5D questionnaire
was unable to distinguish between categories 3, 4, and 5 on the EDSS
[15]. This signifies the inability of the EQ-5D questionnaire to distin-
guish between fully ambulatory patients with MS (EDSS 3) and pa-
tients whose disability is severe enough to impair full daily working
activities (EDSS 5). The MSIS-PBM, of which the physical scale was
knowntobesensitive tochangesbetween level 3, 4, and5,didpickup
the deterioration in health. Neither the QLQ-PBM nor the EQ-5D
questionnaire adequately reflected the deterioration between level 0
and level 1 of theWorld Health Organization performance status.
The QLQ-C30 was, in terms of effect sizemeasured with Cohen’s
d, at times more and at times less sensitive to changes over time
Table 6 – Comparison of utility values derived from the ne
HAQ
N 738
Mean utility (SD) [range]
EQ-5D questionnaire 0.68 (0.23) [0.134 to 1] 0.62
SF-6D 0.66 (0.10) [0.37–1]
PBM* – 0.69
PBM† 0.91 (0.09) [0.57–1] 0.67
Intraclass correlations (ICC)
EQ-5D questionnaire-PBM*† 0.45
EQ-5D, EuroQol five-dimensional; HAQ, Health Assessment Question
non-Hodgkin; PBM, preference-basedmeasure; QLQ, Quality of Life Qu
short form 36 health survey).
* Model based on states from the orthogonal or balanced design.
† Model based on states from the orthogonal design and the most ob
Table 7 – The MSIS-PBM and the QLQ-PBM have increased
Total sample size EQ5D questionnaire 
738 HAQ-PBM  1 n  7
HAQ-PBM  1 –
1295 MSIS-PBM  1 n  99
MSIS-PBM  1 –
1505 QLQ-PBM  1 n  185
QLQ-PBM  1 –
EQ-5D, EuroQol five-dimensional; HAQ-PBM, Health Assessment Que
pact Scale-preference-based measure; QLQ-PMB, Quality of Life QuestionnTable 10). However, the absolute differences indicated that even
hen the QLQ-PBM had a larger mean difference relative to the SD,
he EQ-5D questionnaire still reported larger mean change scores.
Discussion
This study developed three CS-PBMs from existing questionnaires
HAQ, MSIS-29, and QLQ-C30 to provide evidence concerning com-
parability of CS-PBM–derived utility values with generic PBM–de-
rived utility values. CS-PBMs had different mean utility values
within a disease and did not report equal differences in mean
utility values between diseases. The CS-PBMs in this study did not
seem to exaggerate health problems, but rather reported higher
meanvalues.Capturingcomorbiditiesandalong that line sideeffects
of interventions appeared problematic for the HAQ-PBM, but not for
the MSIS-PBM and the QLQ-PBM. The MSIS-PBM and the QLQ-PBM
were more sensitive than the EQ-5D questionnaire to very mild im-
pairment. The physical scale of the MSIS-29 questionnaire is known
to bemore sensitive in discriminating between clinical categories in
MS than is theEQ-5Dquestionnaire. TheMSIS-PBM,derived fromthe
MSIS-29, also has better discriminatory properties.
Because the mean utility values of all three CS-PBMs were
higher than those of generic instruments, it seems that a potential
downward bias of a focusing effectmay be smaller in size than the
upward bias that results from a narrower scope of the condition-
specific measures. This is most clearly seen in the performance of
the HAQ-PBM, which is developed from the HAQ-Disability Index,
which measures functional ability [24]. Consequently, the HAQ-
PBM indicates the utility decrements associated with these func-
tional (dis)abilities. In theHAQ-PBM, there is no dimension such as
“pain” or “psychological state.” Because pain is a frequently occur-
ring symptom in arthritis, it is not surprising that the mean utility
Ms with the EQ-5D questionnaire and the SF-6D.
SIS QLQ_MM QLQ_NH
295 716 789
[0.22 to 1] 0.74 (0.21) [0.058 to 1] 0.73 (0.26) [0.33 to 1]
– – –
[0.40–1] 0.84 (0.09) [0.44–1] 0.82 (0.11) [0.34–1]
[0.42–1] –
.62 0.64 0.67
; MM, multiple myeloma; MSIS, Multiple Sclerosis Impact Scale; NH,
nnaire; SF-6D, six-dimensional health state short form (derived from
d states.
itivity at the ceiling of the EQ-5D questionnaire.
EQ5D questionnaire 1 Worst state for which the
EQ-5D questionnaire  1
– 21211
n  252
– 33111222
n  2
– 24334324
n  4
naire-preference-based measure; MSIS-PBM, Multiple Sclerosis Im-w PB
M
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511V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 0 4 – 5 1 3value of the early arthritis cohort as measured by the HAQ-PBM is
much higher than the mean utility value of the generic instru-
ments; any additional utility decrement besides functional dis-
abilities, such as pain, is not captured directly, if at all. In the case
of the HAQ, this result could have been anticipated on the basis of
the fact that the HAQ-Disability Index aims to offer a unidimen-
sional assessment of functionalities and does not attempt tomea-
sure other dimensions of health because these are captured by
other instruments that are part of the minimum data set interna-
tionally agreed on. The unidimensionality of the HAQ caused
some problems in the valuation task. Because all items aim to
measure the same underlying latent variable (functional ability),
they are highly related. OMEP-generated states have favorable sta-
tistical properties but do not consider the sensibility of the com-
bination of item levels. Consequently, one health state in the val-
uation study consisted of the counterintuitive combination “able
to get up from a chair” and “not able to get up from the toilet.” This
particular state caused confusion with some of the respondents.
The HAQ-Disability Index does not intend to form a comprehen-
sive assessment of relevant disease-specific health outcomes in pa-
tients with rheumatoid arthritis, and therefore could be rejected as
offering a suitable basis for the development of CS-PBMs. The large
deviations inmeanutility valuespresented in this studybetween the
HAQ-PBMand the EQ-5D questionnaire support this view.More gen-
erally, it can be concluded that instruments with a narrow scope,
often identifiable through inspecting items or dimensions, are un-
Table 8 – Comorbidities and side effects by PBM and the EQ
HAQ-PBM
Comorbidity No com
Mean (SD) Median Mean (SD)
Diabetes 0.92 (0.08) 0.9 0.89 (0.10)
Hypercholesterolemia 0.90 (0.09) 0.88 0.89 (0.10)
Thyroid disease 0.90 (0.10) 0.89 0.89 (0.10)
Other cardiac disease 0.86 (0.05) 0.88 0.89 (0.10)
Psychiatric disorder 0.84 (0.13) 0.89 0.89 (0.10)
MSIS-PBM
Comorbidity No com
Mean (SD) Median Mean (SD)
Depression 0.61 (0.12) 0.59* 0.68 (0.14)
Asthma 0.67 (0.14) 0.71 0.67 (0.14)
HBP 0.68 (0.14) 0.73 0.65 (0.13)
QLQ-PBM
Side effects No sid
Mean (SD) Median Mean (SD)
Neurotoxicity† 0.76 (0.09) 0.76* 0.81 (0.09)
Hair loss† 0.8 (0.08) 0.79 0.81 (0.1)
Nausea† 0.73 (0.13) 0.74* 0.81 (0.09)
Other side effects† 0.79 (0.09) 0.8* 0.81 (0.09)
Infection No infe
Ear/nose/throat1 0.72 (0.11) 0.72* 0.81 (0.09)
EQ-5D, EuroQol five-dimensional; HAQ-PBM,HealthAssessmentQuestion
Sclerosis Impact Scale-preference-basedmeasure; QLQ-PMB, Quality of Lif
* Significant difference between comorbidities/no comorbidities at (P
† WHO grade  2.suitable as a base for CS-PBMs used for resource allocation.The perceived insensitivity of existing generic instruments is
an important motive for developing CS-PBMs. In this study, sensi-
tivity of the CS-PBM and the EQ-5D questionnaire was compared
by investigating ceiling effects and discriminative ability of the
instruments between patients with and without comorbidity or
side effects. A ceiling effect found in the EQ-5D questionnaire for
mild impairments was not found in the MSIS-PBM and the QLQ-
PBM (Table 7). One reason for this differencemay be the descrip-
tive system of the questionnaires: the three-level system of the
EQ-5D questionnaire might result in a lower likelihood of re-
porting problems than the four-level systems of the CS-PBMs.
Nevertheless, using CS-PBMs did not result in an exaggeration
of health problems on average when compared with generic
instruments in this study. Rather, the mean utility value of the
MSIS-PBM and the QLQ-PBM was higher than that of the EQ-5D
questionnaire. This may be a reflection of the smaller range in
obtainable utility values, which skews the average upward. Bad
EQ-5D questionnaire health states reflect very poor health,
which is perhaps not captured in the MSIS-PBM and the QLQ-
PBM. Indeed, the negative range of utility values as produced for
the EQ-5D questionnaire has rarely been reproduced for other
instruments. The EQ-5D questionnaire, the MSIS-PBM, and the
QLQ-PBM performed equally well in distinguishing patients
with comorbidities/side effects from patients without it. Only
the HAQ-PBM performed poorly in this aspect. Interestingly, the
MSIS-PBM and the QLQ-PBM displayed equal discriminative
questionnaire.
EQ-5D questionnaire
dity Comorbidity No comorbidity
edian Mean (SD) Median Mean (SD) Median
0.89 0.66 (0.24) 0.79 0.71 (0.16) 0.78
0.89 0.57 (0.27) 0.65 0.72 (0.15) 0.78
0.89 0.60 (0.29) 0.71 0.72 (0.16) 0.78
0.89 0.60 (0.21) 0.68* 0.72 (0.15) 0.78*
0.89 0.54 (0.30) 0.67* 0.72 (0.16) 0.78*
EQ-5D questionnaire
dity Comorbidity No comorbidity
edian Mean (SD) Median Mean (SD) Median
0.68* 0.54 (0.26) 0.64* 0.63 (0.26) 0.67*
0.68 0.63 (0.22) 0.68 0.62 (0.26) 0.67
0.68 0.64 (0.25) 0.64 0.60 (0.26) 0.67
EQ-5D questionnaire
cts Side effects No side effects
edian Mean (SD) Median Mean (SD) Median
0.83* 0.56 (0.27) 0.65* 0.73 (0.25) 0.81*
0.83 0.7 (0.23) 0.78 0.72 (0.26) 0.79
0.83* 0.56 (0.31) 0.65* 0.72 (0.25) 0.81*
0.83* 0.66 (0.23) 0.69* 0.72 (0.26) 0.81*
Infection No infection
0.83* 0.42 (0.32) 0.31* 0.73 (0.25) 0.81*
preference-basedmeasure; HBP, high blood pressure;MSIS-PBM,Multiple
stionnaire-preference-basedmeasure;WHO,World Health Organization.
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512 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 0 4 – 5 1 3smaller total scale size due to a higher “floor” (i.e., the lowest
attainable value).
Superiority of CS-PBMs compared with the EQ-5D question-
naire in regard to their discriminative ability was not demon-
strated for the HAQ-PBM and equivalence was shown for the QLQ-
PBM. The MSIS-PBM showed better discriminative properties than
did the EQ-5D questionnaire in EDSS subcategories. With addi-
tional evidence on known-group differences, this could prove the
MSIS-PBM to be a contribution to cost-utility analyses. The original
preference-based questionnaireMSIS-29was the onlymeasure for
which empirical evidence indicated better discriminative proper-
ties than the EQ-5D questionnaire in MS data sets.
While a CS-PBMmay have desirable statistical properties, such
as expressed in effect size or the ability to identify significant dif-
ferences between groupswith orwithout side effects, partly due to
a small SD of mean values, these properties may not reflect the
absolute size of differences in utility values between groups. This
has consequences for quality-adjusted life-year computation.
Imagine a new drug that reduces nausea from cancer treatments.
Using the figures from Table 8, the population not having nausea
ould have a higher utility with an effect size (Cohen’s d with
pooled SDs) of 0.57 for the EQ-5D questionnaire but a larger 0.73 for
the QLQ-PBM. The absolute difference, however, would be 0.16 for
Table 9 – Discriminant validity.
HAQ-PBM EQ-5D
questionnaire
N
Mean SD Mean SD
DAS-28
Remission 0.98 0.04 0.76 0.20 11
Low DA 0.90 0.08 0.70 0.25 15
Moderate DA 0.90 0.09 0.67 0.22 70
High DA 0.83 0.07 0.51 0.29 27
MSIS-PBM EQ-5D
questionnaire
N
Mean SD Mean SD
EDSS
0 0.80 0.14 0.81 0.22 35
1 0.78 0.14 0.78 0.23 74
2 0.73 0.14 0.72 0.23 262
3 0.68 0.14 0.63 0.25 206
4 0.66 0.13 0.63 0.23 248
5 0.63 0.10 0.64 0.19 103
6 0.60 0.11 0.54 0.25 201
7 0.58 0.11 0.46 0.27 78
8 0.57 0.07 0.40 0.31 17
9 0.47 0.07 0.09 0.10 5
QLQ-PBM EQ-5D
questionnaire
N
Mean SD Mean SD
WHO
0 0.83 0.11 0.75 0.25 356
1 0.83 0.10 0.76 0.24 304
2 0.80 0.11 0.69 0.24 96
3 0.71 0.10 0.37 0.27 27
DA, disease activity; DAS-28, Disease Activity Score-28; EDSS, Ex-
panded Disability Status Scale; EQ-5D, EuroQol five-dimensional;
HAQ-PBM, Health Assessment Questionnaire-preference-based
measure; MSIS-PBM, Multiple Sclerosis Impact Scale-preference-
based measure; QLQ-PMB, Quality of Life Questionnaire-prefer-
ence-based measure; WHO, World Health Organization.the EQ-5D questionnaire and 0.08 for theQLQ-PBM. An implicationof these results is that if a CS-PBM is developed to increase sensi-
tivity comparedwith the EQ-5D questionnaire, statistical sensitiv-
ity is not a sufficient criterion.
Rather than because of concerns about the sensitivity of an
existing generic PBM, a CS-PBM may also be developed because a
PBM was not administered in, for example, a clinical trial. In this
case, one could also choose to use the variation in responses on a
condition-specific measure to estimate what a generic utility in-
strument such as the EQ-5D questionnaire would have been had it
not been absent, a process called mapping [25]. It is important to
reflect on the question which strategy for deriving utilities from a
disease-specific instrument is most appropriate. The main differ-
ence between mapping and constructing a CS-PBM is that the de-
velopment of a PBM assigns population weights (via TTO) to the
item levels of a questionnaire, while a mapping function assigns
weights to the items that are dependent on the generic measure it
aims to estimate. As such, issues with insensitivity of the generic
instrument are not resolved when mapping a condition-specific
measure onto a generic PBM. In our view, a well-conducted and
validated mapping function may be preferred to the development
of a CS-PBM, because it yields utility values that compare better to
the more frequently used generic instruments used in other eco-
nomic evaluations, but only under the following circumstances:
1) there is no empirical evidence for the insensitivity of the generic
instrument, 2) only use of mean utility values is intended rather
than subgroup analysis [26], and 3) the health status or disease
subtype of the sample on which the function was estimated is
comparable to the sample on which the function is applied [15].
Findings here underline that the TTO health state values as
odeled from a fractional factorial design can differ from direct
TO valuations of those states. Often but not always an OMEP is
pplied to allow the estimation of TTO values for all theoretically
ossible health states from only a fraction of health states. This
tudy adopted that technique but also valued directly a selection
f states that were observed frequently in patients. Using these
tates in the estimation of the preference algorithm resulted in
ower scores for at least some of these states (Fig. 1). These results
uggest that discrepancies exist betweenmodeled TTO values and
irectly observed TTO values for themost occurring health states,
hich may affect the validity of the measure. Little guidance is
vailable for researchers who wish to design a valuation study for
CS-PBM by using state-of-the-art techniques, and so it is not
urprising that practices vary and this deserves more attention to
nsure that high-quality CS-PBMs are produced. Ideally, the pro-
ess of constructing the CS-PBM is supported by the original de-
elopers of the questionnaires. This is relevant, for example, to
voidwild growth of value sets (e.g., for the QLQ-C30 nowmultiple
alue sets exist derived via mappings [15,27–29]), to further guar-
ntee quality, and to offer support to users of the CS-PBM.
Table 10 – Responsiveness of utilities in non-Hodgkin
sample.
Follow-up Cohen’s d Mean change
QLQ-PBM EQ-5D QLQ-PBM EQ-5D
Second treatment cycle 0.13 0.17 0.02 0.05
Fourth treatment cycle 0.02 0.08 0.00 0.02
Sixth treatment cycle 0.09 0.06 0.01 0.01
3-mo follow-up 0.33 0.22 0.03 0.06
6-mo follow-up 0.25 0.10 0.02 0.02
10-mo follow-up 0.01 0.09 0.00 0.02
18-mo follow-up 0.00 0.19 0.00 0.04QLQ-PMB,Quality of Life Questionnaire-preference-basedmeasure.
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513V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 5 0 4 – 5 1 3Constructing and using a CS-PBM for the purpose of resource
allocation could be considered when the following conditions are
met: empirical evidence disproves the sensitivity of existing ge-
neric instruments, empirical evidence proves the superiority of
the condition-specific measure from which the new PBM will be
derived, and the derived CS-PBM is shown to be superior to the
existing CS-PBM, not just in terms of statistical sensitivity but also
in terms of absolute differences. The development of CS-PBMs is
welcome from an academic point of view because it pushesmeth-
odological frontiers and introduces new data for comparing mea-
sures in a field where no gold standard PBM exists. Use in resource
allocation of these instruments, however, is warranted only when
the above-mentioned conditions are met. The introduction of
PBMs that are specific to a certain disease has the presupposed
merit of sensitivity to disease-specific effects of interventions, but
this article shows that such an advantage is not necessarily
achieved. Furthermore, the possible increase in sensitivity is
traded off to the loss of comparability of absolute differences in
utility values, which are most important for economic evalua-
tions. It is argued here that without convincing empirical evidence
on the insensitivity of a generic instrument, using a CS-PBM intro-
duces confusion about the appropriate outcomemeasures in cost-
utility analysis and health-care decision making.
Acknowledgments
We thank Prof. B. Uitdehaag from the multiple sclerosis centre of
the VU Medical Centre in Amsterdam and Dr. J. Luime from the
Netherlands Expert Centre for Work-Related Musculoskeletal Dis-
orders, University Medical Center Rotterdam for sharing their ex-
pertise. Furthermore, we thank Mike Horton, from the University
of Leeds, for his suggestions for the Rasch analysis andMark Oppe
for sharing his thoughts on the design of the TTO study. We owe
gratitude to Bart Groenendijk for his aid with setting-up the com-
puter-assisted experiment, to Ming Au for automating the data
extraction, and to Fleur van de Wetering and Sandra de Vries for
their assistance during the TTO exercise.
Source of financial support: This study was funded by ZonMW:
the Netherlands organization for health research and development.
Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at doi:10.1016/j.jval.2011.12.003
or, if a hard copy of article, at www.valueinhealthjournal.com/
issues (select volume, issue, and article).
R E F E R E N C E S
[1] Dolan P. Modeling valuations for the EuroQol health states. Med Care
1997;35:1095–108.
[2] Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-
attribute utility functions for the health utilities index mark 3 system.
Med Care 2002;40:113–28.
[3] Yang Y, Brazier JE, Tsuchiya A, Young TA. Estimating a preference-
based index for a 5-dimensional health state classification for asthma
derived from the Asthma Quality of Life Questionnaire. Med Decis
Making 2011;31:281–91.
[[4] Brazier J, Czoski-Murray C, Roberts J, et al. Estimation of a preference-
based index from a condition-specific measure: the King’s Health
Questionnaire. Med Decis Making 2008;28:113–26.
[5] Brazier J, Tsuchiya A. Preference-based condition-specific measures of
health: what happens to cross programme comparability? Health Econ
2010;19:125–9.
[6] Fryback DG, Lawrence WF. Dollars may not buy as many QALYs as we
think: a problem with defining quality of life adjustments. Med Decis
Making 1997;17:276–84.
[7] Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A. Measuring and Valuing
Health Benefits for Economic Evaluation. New York: Oxford University
Press, 2007.
[8] Brazier JE, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-
5D and SF-6D across seven patient groups. Health Econ 2004;13:873–84.
[9] Kind P, Brooks R, Rabin R, eds. EQ-5D Concepts and Methods: A
Developmental History. Dordrecht, The Netherlands: Springer, 2005.
10] Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a
review of its history, issues, progress, and documentation.
J Rheumatol 2003;30:167–78.
11] Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact
Scale (MSIS-29): a new patient-based outcome measure. Brain 2001;
124:962–73.
12] Aaronson NNK, Ahmedzai S, Bergman B, et al. The European
Organization for Research and Treatment of Cancer QLQ-C30: a
quality-of-life instrument for use in international clinical trials in
oncology. J Natl Cancer Inst 1993;85:365–76.
13] ten Klooster PM, Taal E, van de Laar MAFJ. Rasch analysis of the Dutch
Health Assessment Questionnaire Disability Index and the health
assessment questionnaire II in patients with rheumatoid arthritis.
Arth Care Res 2008;59:1721–8.
14] Ramp M, Khan F, Misajon RA, Pallant JF. Rasch analysis of the Multiple
Sclerosis Impact Scale MSIS-29. Health Qual Life Outcomes 2009;7:58.
15] Versteegh MM, Leunis A, Luime JJ, et al. Mapping QLQ-C30, HAQ, and
MSIS-29 on EQ-5D. Med Decis Making 2011; (online first)
16] Young TA, Yang Y, Brazier JE, Tsuchiya A. The use of Rasch analysis in
reducing a large condition-specific instrument for preference
valuation. Med Decis Making 2011;31:195–210.
17] Mavranezouli I, Brazier JE, Young TA, Barkham M. Using Rasch
analysis to form plausible health states amenable to valuation: the
development of CORE-6D from a measure of common mental health
problems (CORE-OM). Qual Life Res 2011;20:321–33.
18] Pallant JF, Tennant A. An introduction to the Rasch measurement
model: an example using the Hospital Anxiety and Depression Scale
(HADS). Br J Clin Psychol 2007;46(Pt 1):1–18.
19] Tennant A, McKenna SP, Hagell P. Application of Rasch analysis in the
development and application of quality of life instruments. Value
Health 2004;7:s22–6.
20] Brazier JE, Roberts J, Platts M, Zoellner YF. Estimating a preference-
based index for a menopause specific health quality of life
questionnaire. Health Qual Life Outcomes 2005;3:13.
21] Brazier J, Roberts J, Deverill M. The estimation of a preference based
measure of health from the SF-36. J Health Econ 2002;21:271–92.
22] Lamers LM, McDonnell J, Stalmeier PFM, et al. The Dutch tariff: results
and arguments for an effective design for national EQ-5D valuation
studies. Health Econ 2006;15:1121–32.
23] Stolk EA, Busschbach JJ. Validity and feasibility of the use of
condition-specific outcome measures in economic evaluation. Qual
Life Res 2003;12:363–71.
24] Bruce B, Fries JF. The StanfordHealth Assessment Questionnaire:
dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
25] Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping
(or cross walking) non-preference based measures of health to generic
preference-based measures. Eur J Health Econ 2010;11:215–25.
26] Versteegh M, Rowen D, Brazier J, Stolk E. Mapping onto EQ-5D for
patients in poor health. Health Qual Life Outcomes 2010;8:141.
27] Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D. Mapping the
cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D,
and 15D instruments. Value Health 2009;12:1151–7.
28] McKenzie L, Van der Pol M. Mapping the EORTC QLQ C-30 onto the EQ-
5D instrument: the potential to estimate QALYs without generic
preference data. Value Health 2009;12:167–71.29] Crott R, Briggs A.Mapping theQLQ-C30Quality of Life Cancer Questionnaire
to EQ-5D patient preferences. Euro J Health Econ 2010;11:427–34.
